About Biojo Sciences

Biojo Sciences is a global biopharmaceutical company that develops novel clinical-stage therapies to improve patient and family lives. Our efficient development process identifies and delivers compelling clinical-stage biotechnologies through effective operations in an innovative portfolio biotech company. We bring clinical-stage drug assets to commercialization through licensing and partnerships. Our team has deep industry knowledge of the latest science, regulatory pathways, and business strategies. Our portfolio targets a diverse range of diseases and technologies, including oncology, neurology, rare diseases, and cell & gene platforms.

Our mission at Biojo Sciences is to focus on creating therapeutic value for patients, for innovative science, and for our stakeholders.

Jenny (Seungyun) Jo

Founder & CEO

Biojo operates to accelerate clinical development with improved processes and operations. We deploy our expertise in business, regulatory, scientific, and financial experience to acquire rights to clinically and commercially promising therapies. Biojo Sciences builds a diversified and robust portfolio through licensing, joint ventures, and strategic partnerships. In addition, we reduce risk by diversifying our pipeline with different therapeutic areas and technologies.

The strength in the Biojo model is in tailoring the process support each specific therapy needs. This injects value to developing drugs by improving the potential for commercial and long-term returns.

Therapeutics Focus

Our team identifies new therapeutic opportunities through deep industry networks, using decades of biopharma experience, and a dedicated approach.

Using Our Capital

Our capital is used for acquiring rights to therapies, world-class resources & support, and clinical development. We use our capital to invest for long-term returns through acquiring high potential therapies and funding clinical development.

Powerful Partnerships

As one of our guiding principles, we are committed to sound collaboration and creating powerful partnerships. We use our combined capabilities to maximized potential opportunities.

Patients around the world are in need of rapidly developing life changing therapies. The advancement of innovative therapies brings treatments to diseases that have an unmet need. Biojo Sciences is committed in identifying and developing these promising medicines. When it comes to the benefits of new therapies, our mission is to provide the necessary development and funding structures needed to bring novel drugs from R&D to commercialization.

The journey for new therapies involves strong leadership, collaboration with a broad range of specialties, and for a company to demonstrate integrity. It is important that our team at Biojo Sciences conduct our business with the commitment to adding value to much needed therapies that pursue to improve patient outcomes.

Our Model

Biojo operates to accelerate clinical development with improved processes and operations. We deploy our expertise in business, regulatory, scientific, and financial experience to acquire rights to clinically and commercially promising therapies.

Read More...
Biojo Sciences builds a diversified and robust portfolio through licensing, joint ventures, and strategic partnerships. In addition, we reduce risk by diversifying our pipeline with different therapeutic areas and technologies.

The strength in the Biojo model is in tailoring the process support each specific therapy needs. This injects value to developing drugs by improving the potential for commercial and long-term returns.

Our Approach

Therapeutics Focus

Our team identifies new therapeutic opportunities through deep industry networks, using decades of biopharma experience, and a dedicated approach.
Read More...

Using Our Capital

Our capital is used for acquiring rights to therapies, world-class resources & support, and clinical development. We use our capital to invest for long-term returns through acquiring high potential therapies and funding clinical development.

Powerful Partnerships

As one of our guiding principles, we are committed to sound collaboration and creating powerful partnerships. We use our combined capabilities to maximized potential opportunities.

Patients First

Patients around the world are in need of rapidly developing life changing therapies. The advancement of innovative therapies brings treatments to diseases that have an unmet need. Biojo Sciences is committed in identifying and developing these promising medicines.

Read More...
When it comes to the benefits of new therapies, our mission is to provide the necessary development and funding structures needed to bring novel drugs from R&D to commercialization.

The journey for new therapies involves strong leadership, collaboration with a broad range of specialties, and for a company to demonstrate integrity. It is important that our team at Biojo Sciences conduct our business with the commitment to adding value to much needed therapies that pursue to improve patient outcomes.

1.9M

new cancer cases
in the US alone

$100M

first series fund

25+

average years
of experience

1.9M

new cancer cases
in the US alone

$100M

first series fund

25+

average years
of experience

Pipeline

Biojo is building a diversified and robust portfolio. Our prospective pipeline has the flexibility to add therapies in different therapeutic areas in mid-stage clinical development.

ASCO Annual Meeting 2024

The American Society of Clinical Oncology (ASCO) Annual Meeting…

Biotechgate Digital Partnering May 2024

Biojo Sciences will attend the Biotechgate Digital Partnering virtual…

BIO International Convention 2023

The BIO International Convention is the world's largest gathering…

Subscribe to receive our latest news


Contact Us

United States

Biojo Sciences

3 Bethesda Metro Center, Suite 700
Bethesda, Maryland 20814
United States of America
+1 (301) 961-4890

South Korea

(주) 바이오조 사이언시스

#502, 397 Seocho-daero,
Seocho-gu, Seoul 06616
Republic of Korea
+82 2-3477-2022

Send us mail

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.